<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03151876</url>
  </required_header>
  <id_info>
    <org_study_id>ChiCGB-DLBCL</org_study_id>
    <nct_id>NCT03151876</nct_id>
  </id_info>
  <brief_title>Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma</brief_title>
  <official_title>Chidamide Combined With Cladribine/Gemcitabine/Busulfan (ChiCGB) With Autologous Stem-Cell Transplantation in Relapsed and Refractory Diffuse Large B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to evaluate effectiveness and safety of ChiCGB&#xD;
      regimen( chidamide, cladribine, gemcitabine and busulfan).&#xD;
&#xD;
      Busulfan are designed to kill cancer cells by binding to DNA (the genetic material of cells),&#xD;
      which may cause cancer cells to die.&#xD;
&#xD;
      Gemcitabine and cladribine are designed to disrupt the growth of cancer cells, which may&#xD;
      cause cancer cells to die. It may help to increase the effect of busulfan on cancer cells by&#xD;
      not allowing these cells to repair the DNA damage caused by busulfan.&#xD;
&#xD;
      Chidamide is designed to open up the DNA and allow greater access to drugs that bind to DNA,&#xD;
      such as cladribine, gemcitabine, busulfan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Groups:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be enrolled in a group&#xD;
      of at least 3 participants to begin receiving the study drugs.&#xD;
&#xD;
      The dose of the study drugs you receive will depend on when you enrolled in this study. If no&#xD;
      intolerable side effects occur in your group, researchers will continue to enroll&#xD;
      participants at the next dose level until either the vorinostat reaches the dose level&#xD;
      currently used alone without stem cell transplant, or the highest tolerable dose of this drug&#xD;
      is found. The dose that you receive will remain the same throughout this study.&#xD;
&#xD;
      You will be admitted to the hospital on Day -6.&#xD;
&#xD;
      Study Drug Administration (for all patients):&#xD;
&#xD;
      In stem cell transplant, the days before you receive your stem cells are called minus days.&#xD;
      The day you receive the stem cells is called Day 0. The days after you receive your stem&#xD;
      cells are called plus days.&#xD;
&#xD;
      On Day -7, -4, 0, +3 , you will take chidamide by mouth.&#xD;
&#xD;
      On Days -6, -5, -4, -3, and -2 you will receive cladribine by vein over 1/2 hours.&#xD;
&#xD;
      On Day -6, -2, you will receive gemcitabine by vein over 3 1/2 - 4 1/2 hours.&#xD;
&#xD;
      On Days -6, -5, -4, and -3, you will receive busulfan by vein over 3 hours.&#xD;
&#xD;
      On Day -1, you will rest.&#xD;
&#xD;
      On Day 0, you will receive your stem cells by vein over about 30-60 minutes.&#xD;
&#xD;
      As part of standard care, you will receive G-CSF (filgrastim) as an injection just under your&#xD;
      skin twice a day starting on Day +5 until your blood cell levels return to normal.&#xD;
&#xD;
      Study Tests:&#xD;
&#xD;
      On Day -1, you will have an electrocardiogram (ECG) to check your heart function.&#xD;
&#xD;
      About 30-100 days after the transplant, you will have lung function tests.&#xD;
&#xD;
      About 100 days after the transplant:&#xD;
&#xD;
      Blood (about 4 teaspoons) will be drawn for routine tests. If the doctor thinks it is needed,&#xD;
      you may have a bone marrow aspiration and biopsy to check the status of the disease.&#xD;
&#xD;
      You will have a PET/CT scan of your whole body to check the status of the disease.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      As part of standard care, you will remain in the hospital for about 3-4 weeks after the&#xD;
      transplant. After you are released from the hospital, you will continue as an outpatient for&#xD;
      infections and transplant-related complications.&#xD;
&#xD;
      You will be taken off study about 100 days after the transplant. You may be taken off study&#xD;
      early if the disease gets worse, if intolerable side effects occur, or if you are unable to&#xD;
      follow study directions.&#xD;
&#xD;
      This is an investigational study. Chidamide, gemcitabine, busulfan, melphalan, and rituximab&#xD;
      are all FDA approved and commercially available. The use of these study drugs in combination&#xD;
      is investigational.&#xD;
&#xD;
      Up to 93 patients will take part in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>ChiCGB</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission</measure>
    <time_frame>3 month after autologous hematopoietic stem cell transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">93</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>ChiCGB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: ChiCGB&#xD;
Chidamide administered orally on D-7, -4, 0,+3&#xD;
Cladribine administered at 10mg on D-6 to D-2&#xD;
Gemcitabine administered at 2500 mg/m2 on days -6 and -2.&#xD;
Busulfan administered at 3.2 mg/kg (adjusted ideal body weight) on days -6 to -3.&#xD;
Dexamethasone 10 mg by vein daily from day -6 to day -1. Caphosol oral rinses 30 mL four times a day used from day -8.&#xD;
Interventions:&#xD;
Drug: Chidamide Drug: Cladribine Drug: Gemcitabine Drug: Busulfan Drug: Dexamethasone Procedure: Stem Cell Transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide</intervention_name>
    <description>30 mg oral twice weekly for 2 weeks</description>
    <arm_group_label>ChiCGB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>6 mg/m2 intravenously daily for 5 days</description>
    <arm_group_label>ChiCGB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>2500 mg/m2 intravenously twice weekly for 1 week</description>
    <arm_group_label>ChiCGB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>3.2 mg/kg intravenously daily for 4 days</description>
    <arm_group_label>ChiCGB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous hematopoietic stem cell transplantation</intervention_name>
    <description>autologous hematopoietic stem cells infusion after ChiCGB chemotherapy</description>
    <arm_group_label>ChiCGB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with primary refractory or recurrent diffuse large B cell lymphoma that do&#xD;
             not qualify for treatment protocols of higher priority.&#xD;
&#xD;
          2. Relapsed patients should respond to 2nd or 3rd line salvage chemotherapy and attain at&#xD;
             least PR before recruitment.&#xD;
&#xD;
          3. Adequate renal function, as defined by estimated serum creatinine clearance &gt;/=50&#xD;
             ml/min and/or serum creatinine &lt;/= 1.8 mg/dL.&#xD;
&#xD;
        6. Adequate hepatic function, as defined by serum glutamate oxaloacetate transaminase&#xD;
        (SGOT) and/or serum glutamate pyruvate transaminase (SGPT) &lt;/= 3 x upper limit of normal;&#xD;
        serum bilirubin and alkaline phosphatase &lt;/= 2 x upper limit of normal.&#xD;
&#xD;
        7. Adequate pulmonary function with forced expiratory volume at one second (FEV1), forced&#xD;
        vital capacity (FVC) and diffusing capacity of lung for carbon monoxide (DLCO) &gt;/= 50% of&#xD;
        expected corrected for hemoglobin.&#xD;
&#xD;
        8. Adequate cardiac function with left ventricular ejection fraction &gt;/= 50%. No&#xD;
        uncontrolled arrhythmias or symptomatic cardiac disease.&#xD;
&#xD;
        9. Performance status 0-1. 10. Negative Beta diffusing capacity of lung for carbon monoxide&#xD;
        (HCG) text in a woman with child-bearing potential, defined as not post-menopausal for 12&#xD;
        months or no previous surgical sterilization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Central nervous system lymphoma&#xD;
&#xD;
          2. Patients relapsed after ASCT&#xD;
&#xD;
          3. Bone marrow was involved by lymphoma&#xD;
&#xD;
          4. Patients with active hepatitis B or C(HBV DNA &gt;/=10,000 copies/mL).&#xD;
&#xD;
          5. Active infection requiring parenteral antibiotics&#xD;
&#xD;
          6. HIV infection, unless the patient is receiving effective antiretroviral therapy with&#xD;
             undetectable viral load and normal cluster of differentiation 4 (CD4) counts&#xD;
&#xD;
          7. Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic&#xD;
             hepatitis C or positive hepatitis C serology.&#xD;
&#xD;
          8. Patients with a cQT longer than 500 ms&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ting Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Ji, MD</last_name>
    <phone>86-28-85422370</phone>
    <email>JieJi@scu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ting Liu, MD</last_name>
    <phone>86-28-85422373</phone>
    <email>liuting@scu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing cancer hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yan Xie, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking university third hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaoyan Ke, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of Chongqing medical university</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lin Liu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southwest Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dabing Qin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Lanzhou military command</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730070</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hai Bai, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan cancer hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jian Zhou, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of Zhengzhou university</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xinhua Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yang Cao, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu province hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Xu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rui jin hospital Shanghai jiao tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiong Hu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tong Ren Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ligen L i u, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shan Xi Da Yi Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rong Gong, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tangdu Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qiang Liu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Ji, MD</last_name>
      <phone>86-28-85422370</phone>
      <email>jieji@scu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Southwest Medical University</name>
      <address>
        <city>Nanchong</city>
        <state>Sichuan</state>
        <zip>646000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoming Li, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blood diseases hospital, Chinese academy of medica</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjing</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lvgui Qiu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of Xinjiang medical Universtiy</name>
      <address>
        <city>Ürümqi</city>
        <state>Xinjiang</state>
        <zip>830054</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ming Jiang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kunming General Hospital of Chengdu Military Area</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sanbin Wang, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>May 5, 2017</study_first_submitted>
  <study_first_submitted_qc>May 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>July 16, 2018</last_update_submitted>
  <last_update_submitted_qc>July 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan University</investigator_affiliation>
    <investigator_full_name>Jie Ji</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>electronic case report form (eCRF)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

